Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2025-01-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000003417 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593958692192256 |
|---|---|
| author | Rui Huang Chunli Zhang Xiaodong Mo Huiying Rao Rongman Jia |
| author_facet | Rui Huang Chunli Zhang Xiaodong Mo Huiying Rao Rongman Jia |
| author_sort | Rui Huang |
| collection | DOAJ |
| format | Article |
| id | doaj-art-c6a508231e2448e1b5765637ae4115f0 |
| institution | Kabale University |
| issn | 0366-6999 2542-5641 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj-art-c6a508231e2448e1b5765637ae4115f02025-01-20T07:56:42ZengWolters KluwerChinese Medical Journal0366-69992542-56412025-01-01138212712910.1097/CM9.0000000000003417202501200-00001Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatideRui Huang0Chunli Zhang1Xiaodong Mo2Huiying Rao3Rongman Jia1 Peking University People’s Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People’s Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing 100044, China2 Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China3 Peking University People’s Hospital, Department of Hematology, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China1 Peking University People’s Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People’s Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing 100044, Chinahttp://journals.lww.com/10.1097/CM9.0000000000003417 |
| spellingShingle | Rui Huang Chunli Zhang Xiaodong Mo Huiying Rao Rongman Jia Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide Chinese Medical Journal |
| title | Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide |
| title_full | Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide |
| title_fullStr | Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide |
| title_full_unstemmed | Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide |
| title_short | Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide |
| title_sort | outbreak of metabolic dysfunction associated steatohepatitis pharmacotherapies in 2024 from resmetirom to tirzepatide |
| url | http://journals.lww.com/10.1097/CM9.0000000000003417 |
| work_keys_str_mv | AT ruihuang outbreakofmetabolicdysfunctionassociatedsteatohepatitispharmacotherapiesin2024fromresmetiromtotirzepatide AT chunlizhang outbreakofmetabolicdysfunctionassociatedsteatohepatitispharmacotherapiesin2024fromresmetiromtotirzepatide AT xiaodongmo outbreakofmetabolicdysfunctionassociatedsteatohepatitispharmacotherapiesin2024fromresmetiromtotirzepatide AT huiyingrao outbreakofmetabolicdysfunctionassociatedsteatohepatitispharmacotherapiesin2024fromresmetiromtotirzepatide AT rongmanjia outbreakofmetabolicdysfunctionassociatedsteatohepatitispharmacotherapiesin2024fromresmetiromtotirzepatide |